EXEL - Exelixis slumps amid Cabometyx patent trial
2023-10-23 10:44:57 ET
More on Exelixis
- Exelixis: Predominantly Single Molecule Cancer Franchise (Rating Downgrade)
- Exelixis: Positive Advanced Pancreatic/Extra-Pancreatic Neuroendocrine Tumor Data Brings 2 Big Catalysts On Deck
- Exelixis: Long-Term Problem Isn't Shareholder Activism - It's Cabo Patent Expiry
- Exelixis started at buy at Wainwright on targeted oncology pipeline
- Exelixis inks licensing deal with Insilico for tumor candidate
For further details see:
Exelixis slumps amid Cabometyx patent trial